RegeneRx Issues Letter To Stockholders

On April 11, 2023, RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) issued a Letter to Stockholders outlining its operational strategy and development focus.

Rhea-AI Summary

On April 11, 2023, RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) issued a Letter to Stockholders outlining its operational strategy and development focus. The company specializes in novel therapeutic peptides, particularly Thymosin beta 4 (Tβ4), targeting tissue protection, repair, and regeneration. RegeneRx is advancing three drug candidates in clinical trials for various medical conditions and holds four strategic licensing agreements across the U.S., China, and several Asian countries, as well as the EU. The letter includes forward-looking statements regarding financial needs, clinical trials, and partnerships, highlighting inherent risks and uncertainties, particularly concerning capital requirements and the success of ongoing clinical trials.

Positive

• Three drug candidates currently in clinical development.
• Four active strategic licensing agreements in multiple regions.

Negative

• Uncertainties regarding the ability to raise capital for operations.
• No guarantee of success in ongoing clinical trials.

Argus Session date unavailable

-57.50% session move Open Argus

Details

News Market Reaction – RGRX

The recorded move for RGRX in the trading session of this news was -57.50%.

Data tracked by StockTitan Argus. Session date unavailable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

ROCKVILLE, Md., April 11, 2023 /PRNewswire/ -- RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) ("the Company" or "RegeneRx"), a clinical-stage drug development company focused on tissue protection, repair, and regeneration, has issued a Letter to Stockholders updating its ongoing operating strategy.  The Letter may be viewed at RegeneRx's homepage: www.regenerx.com.

About RegeneRx Biopharmaceuticals, Inc.

RegeneRx is focused on the development of novel therapeutic peptides, including Thymosin beta 4 (Tβ4) and its constituent fragments, for tissue and organ protection, repair, and regeneration. RegeneRx currently has three drug candidates in clinical development for ophthalmic, acute inflammatory and dermal indications, four active strategic licensing agreements in the U.S., China, and Pan Asia (Korea, Japan, and Australia, among others), and the EU, and has patents and patent applications covering its products in many countries throughout the world.

Forward Looking Statements

Any statements in this press release and Letter to Stockholders that are not historical facts are forward-looking statements made under the provisions of the Private Securities Litigation Reform Act of 1995. Any forward-looking statements involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements.  Forward-looking statements in this stockholder letter include, but are not limited to, statements regarding our current or future cash position, capital requirements, ability to continue operations, strategic and research partnerships, the development and timing of clinical trials for our drug candidates, the use of our drug candidates to treat various conditions, our operating strategies, intellectual property, and our financial needs.  These, and any other forward-looking statements, are expectations and estimates based upon information obtained from our joint venture partner and/or calculated by the Company at this time and are subject to change.  Moreover, there is no guarantee any of our clinical trials will be successful or confirm previous clinical results.  There also is no assurance that we can successfully raise the capital required to continue even limited business operations now or in the future.  Please view these and other risks described in the Company's filings with the Securities and Exchange Commission ("SEC"), including those identified in the "Risk Factors" section of the annual report on Form 10-K for the year ended December 31, 2022, and subsequent quarterly reports filed on Form 10-Q, as well as other filings it makes with the SEC, if any.  Any forward-looking statements in this stockholder letter represent the Company's views only as of the date of this letter and should not be relied upon as representing its views as of any subsequent date. The Company specifically disclaims any obligation to update this information, as a result of future events or otherwise, except as required by applicable law.

View original content:https://www.prnewswire.com/news-releases/regenerx-issues-letter-to-stockholders-301794921.html

SOURCE RegeneRx Biopharmaceuticals, Inc.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did RegeneRx announce on April 11, 2023?

RegeneRx announced a Letter to Stockholders updating its operational strategy and clinical development focus.

What are the main drug candidates developed by RegeneRx?

RegeneRx's main drug candidates focus on therapeutic peptides, particularly Thymosin beta 4 (Tβ4) for various medical conditions.

What risks are associated with RegeneRx's forward-looking statements?

The risks include uncertainties in capital requirements, the success of clinical trials, and operational capabilities.

How many licensing agreements does RegeneRx currently have?

RegeneRx has four active strategic licensing agreements across different regions.

What is the focus of RegeneRx's clinical development?

RegeneRx focuses on tissue protection, repair, and regeneration through its therapeutic peptides.